medigraphic.com
ISSN 0016-3813 (Print)

2007, Number 3

<< Back Next >>

Gac Med Mex 2007; 143 (3)

Elevada mortalidad y discapacidad en niños mexicanos con enfermedad de orina con olor a jarabe de arce (EOJA)

Ibarra-González I, Fernández-Lainez C, Belmont-Martínez L, Vela-Amieva M

Language: Spanish
References: 23
Page: 197-201
PDF size: 75.38 Kb.


ABSTRACT

Introduction: Maple syrup urine disease (MSUD) is a genetic disorder that produces ketoacidosis crises and neurological complications often leading to death. The age of diagnosis and treatment determine a child´s adequate and healthy outcome. Objective: Describe the characteristics of a pediatric Mexican cohort with MSUD.
Material and methods: Retrospective analysis of MSUD cases seen at our Metabolic Unit between 1991- 2006.
Results: We studied 36 patients; three were initially detected through neonatal screening, one of them done in Mexico and two in the United States. The latter were given timely treatment and developed normally, both intellectually and physically. The patient detected in Mexico was not given adequate treatment and died at 3 months of age. The remaining 33 patients were diagnosed between 2-24 months using standard biochemical tests performed after symptoms became noticeable. All symptomatic patients had high levels of branched-chain amino acids. Hypotonia, refusal to eat and seizures were the most frequent symptoms. The cohort’s mortality was 50% (18/36), while 81.2% (13/18) of survivors displayed cognitive impairment.
Discussion: Mexico needs a comprehensive treatment protocol for the care of MSUD patients including newborn screening, early treatment, follow-up and genetic counseling.


REFERENCES

  1. Garg U, Dasouki M. Expanded newborn screening of inherited metabolic disorders by tandem mass spectrometry: Clinical and laboratory aspects. Clin Biochem 2006;39:315-332.

  2. Simon E, Wendel U, Schadewaldt P. Maple syrup urine disease-treatment and outcome in patients of turkish descent in Germany. Turk J Pediatr 2005;47:8-13.

  3. Cederbaum S. Phenylketonuria: an update. Curr Opin Pediatr 2002;14:702-706.

  4. National Center for Biotechnology Information. OMIM: Online Mendelian Inheritance in Man [database]. Available at: www.ncbi.nlm.nih.gov/entrez/query.fcgi?db_OMIM. Accessed sept 18, 2006.

  5. Chuang DT, Shih VE. Maple Syrup Urine Disease (Branched-Chain Ketoaciduria). En: The Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet AL, Valle D (Eds.) McGraw-Hill Inc., 8a Edición, New York, EUA, 2001, pp 1991-1995.

  6. Ogier de Baulny H, Saudubray JM. Branched-Chain Organic Acidurias. En: Inborn Metabolic Diseases Diagnosis and Treatment. Fernandes J, Saudubray JM, Van den Berghe G (Eds.) Springer, 3a Edición, New York, EUA, 2000, pp 197.

  7. Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI. Diagnosis and treatment of Maple Syrup Urine Disease: A study of 36 Patients. Pediatrics 2002;109:999-1007.

  8. Kaye CI, Committee on Genetics; Accurso F, La Franchi S, Lane PA, Hope N, Sonya P, G Bradley S, Michele A LP. Newborn screening fact sheets. Pediatrics 2006;118:934-963.

  9. Deng C, Deng Y. Diagnosis of maple syrup urine disease by determination of L-valine, L-isoleucine, L-leucine and L-phenylalanine in neonatal blood spots by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 792:261-268.

  10. Tajima G, Yofune H, Bahagia Febriani AD, Nishimura Y, Ono H, Sakura N. A simple and rapid enzymatic assay for the branched-chain alpha-ketoacid dehydrogenase complex using high performance liquid cromatography. J Inherit Metab Dis 2004;27:633-639.

  11. Rogríguez-Pombo P, Navarrete R, Merinero B, Gomez-Puertas P, Ugarte M. Mutational spectrum of maple syrup urine diasease in Spain. Hum Mutat 2006;27:715.

  12. Chuang DT, Chuang JL, Wynn RM. Lessons from genetic disorders of branched-chain amino acid metabolism. J Nutr 2006;136(1 Suppl):243S-249S.

  13. Strauss KA, Mazariegos GV, Sindhi R, Squires R, Finegold DN, Vockley G, et al. Elective liver transplantation for the treatment of classical maple syrup urine disease. Am J Transplant 2006;6:557-564.

  14. Khanna A, Hart M, Nyhan WL, Hassanein T, Panyard-Davis J, Barshop BA. Domino liver transplantation in maple syrup urine disease. Liver Transpl 2006;12:876-882.

  15. Snyderman SE. In response to le Roux et al. J Inherit Metab Dis 2006;29:690.

  16. le Roux C, Murphy E, Lilburn M, Lee PJ. The longest-surviving patient with classical maple syrup urine disease. J Inherit Metab Dis. 2006;29:190-194.

  17. Norma Oficial Mexicana-007-SSA2-1993. Atención a la mujer durante el embarazo, parto y puerperio y del RN, criterios y procedimientos para la prestación del servicio. Diario Oficial de la Federación Tomo CDXCVI No.5 México, D.F. viernes 6 de enero de 1995.

  18. Velázquez A, Vela M, Ciceron I, Ibarra I, Pérez M, Olivares Z, et al. Diagnosis of inborn errors of metabolism. Arch Med Res 2000;31:145-150.

  19. Lin JF, Chiu PC, Hsu HY, Lin SM, Chen YY, Hsieh KS. An early diagnosis leads to a good prognosis: a patient with maple syrup urine disease –screened by tandem mass spectrometry. Acta paediatr Taiwán 2004;45:287-289.

  20. Heldt K, Schwahn B, Marquardt I, Grotzke M, Wendel U. Diagnosis of MSUD by newborn screening allows early intervention without extraneous detoxification. Mol Genet Metab 2005;84:313-316.

  21. Lloyd-Puryear MA, Tonniges T, van Dyck PC, Mann MY, Brin A, Johnson K, et al. American Academy of Pediatrics Newborn Screening Task Force recommendations: how far have we come? Pediatrics 2006;117:S194-S211.

  22. Korein J, Sansaricq C, Kalmijn M, Honig J, Lange B. Maple syrup urine disease: clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity. Int J Neurosci 1994;79:21-45.

  23. Riviello JJ Jr, Rezvani I, DiGeorge AM, Foley CM. Cerebral edema causing death in children with maple syrup urine disease. J Pediatr 1991;119:42-45.




2020     |     www.medigraphic.com